Microlyte® Matrix and Microlyte® Surgical featured in clinical research presented at SAWC

Madison, WI, October 12th, 2021 – Imbed Biosciences is proud to announce that research conducted using Microlyte Matrix and Microlyte Surgical will be presented in a panel discussion at SAWC, a national wound healing conference.

Imbed Biosciences announced today that clinical results documenting the use of its products, Microlyte® Matrix and Microlyte® SURGICAL, will be presented at the Fall Symposium on Advanced Wound Care (SAWC) in Las Vegas, NV from October 29th to 31st, 2021. SAWC is the nation’s largest interdisciplinary wound care forum.
Seven poster presentations, delivered by several of Imbed’s clinical collaborators, will highlight results in a variety of complex, chronic wounds and surgical applications, including: radiation breast wounds, lower extremity ulcers, a transmetatarsal amputation on a severely immunocompromised patient, wide excisional debridement of a pilonidal cyst, and a variety of home health cases including intertriginous dermatitis, a surgical dehiscence, and a traumatic crush injury. These clinical cases were conducted independently at the following institutions: Great Falls Clinic Wound Care Center (Great Falls, Montana), Temple University School of Podiatric Medicine, (Philadelphia, PA), Mount Sinai Hospital (New York, NY), Methodist Hospital For Surgery (Addison, TX), ProHealthcare, LLC (Dallas, TX), and Caritas Home Care (Dallas, TX).
Imbed will also host an hour-long Innovation Theater on Sunday 10/31 entitled “Intraoperative Management of Wounds Using Microlyte® SURGICAL” where Imbed co-founder Michael Schurr, MD will moderate a panel discussion on the use of Microlyte® SURGICAL in the operating room. The panel will include John C. Lantis, MD of Mount Sinai West Hospital (New York, NY), Ryan Chatelain, DPM of East Tennessee State University (Johnson City, TN), Shannon Payseur, MD of Methodist Hospital For Surgery (Addison, TX), and William Shillinglaw, DO of Mission Hospital (Ashville, NC).
Poster presentations:
1. (CS-002) A Bioresorbable Antimicrobial Nanoparticle Matrix: The “Swiss Army Knife” of Wound Matrix Dressings. Angie Machado, LVN, WCC, WCN-C, Dallas, Texas
2. (CS-007) Clinical Advantage of a Bioresorbable Silver Matrix on Radiation Breast Wounds. Amanda Murray, NP-C, MSN, WCC, Great Falls Clinic Wound Care Center, Great Falls, Montana
3. (CS-039) Use of Bioresorbable Polymeric Matrix with Silver during the Proliferation Phase of Wound Healing: An Effective Treatment Regimen. Alex Khan, APN, PRO HEALTHCARE, LLC, Dallas, Texas
4. (CS-044) Using a Multimodal Hygiene-Focused Approach to Management of Chronic Wounds of the Lower Extremity Utilizing HOCl and a Bioresorbable Antimicrobial Nanoparticle Matrix. James McGuire, DPM, PT, LPed, FAPWHc, Temple University School of Podiatric Medicine, Philadelphia, Pennsylvania
5. (CS-088) Addition of a Bioresorbable Silver Matrix to Close a Non-Healing Transmetatarsal Amputation Site on a Diabetic Patient. Shannon Payseur, MD, Methodist Hospital For Surgery, Dallas, Texas
6. (CS-089) Combination Use of a Bioresorbable Silver Matrix and NPWT following Wide Excisional Debridement of a Pilonidal Cyst. Shannon Payseur, MD, Methodist Hospital For Surgery, Dallas, Texas
7. (CR-014) Simultaneous Use of 3D Extracellular Wound Matrix and Antimicrobial Bioresorbable Matrix on Lower Extremity Wounds with Bacterial Impediment to Heal. Crystal James, MD, Mount Sinai Hospital, New York, NY
“These research posters and panel discussion are the latest demonstrations of what Microlyte® Matrix and Microlyte® Surgical can do in treating challenging wounds of varying etiologies,” said Jeff Dalsin, PhD, Imbed’s Vice President of Operations. “We hear every day how Microlyte® Matrix is changing people’s lives. That makes our work exceptionally gratifying.”
The Microlyte® family of products are primarily composed of an ultrathin, resorbable polymeric film, which means it never needs to be removed from the wound bed. Microlyte® wound matrices are also fully synthetic, so there is no risk of disease transmission from animal based-components, and they have a long shelf-life under ambient conditions (2 years or more). Microlyte® Matrix and Microlyte® Surgical are cleared for application in acute wounds such as lacerations, skin tears, abrasions, surgical wounds (e.g., donor and graft sites, incisions), partial thickness first- and second-degree burns, and partial to full-thickness dermal ulcers such as, diabetic, decubitus, venous stasis, arterial stasis ulcers.

You can find Ryan Chatelain’s research in the upcoming edition of WOUNDS, a peer reviewed journal.

The online version of the article may be found at https://www.hmpgloballearningnetwork.com/site/wounds/case-series/efficacy-novel-silver-containing-bioresorbable-microfilm-matrix-risk

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held biotech company registered with FDA as a medical device manufacturer with an ISO 13485 certified quality management system. The company has a portfolio of products in development based on its patented Microlyte® technology to combat local pain and infections in complex wounds such as burns, chronic ulcers, surgical wounds, epidermolysis bullosa, and colorectal surgeries. A portion of Imbed’s research funding comes from the National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS). For more information, visit http://www.imbedbio.com.